Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design.

[1]  Douglas G. Altman,et al.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design , 2019, BMJ.

[2]  Lingyun Liu,et al.  Adaptive Designs: Results of 2016 Survey on Perception and Use. , 2018, Therapeutic innovation & regulatory science.

[3]  A. Sato,et al.  Practical characteristics of adaptive design in phase 2 and 3 clinical trials , 2018, Journal of clinical pharmacy and therapeutics.

[4]  Jay J H Park,et al.  Critical concepts in adaptive clinical trials , 2018, Clinical epidemiology.

[5]  Kristian Thorlund,et al.  Key design considerations for adaptive clinical trials: a primer for clinicians , 2018, British Medical Journal.

[6]  Lisa V. Hampson,et al.  Adaptive designs in clinical trials: why use them, and how to run and report them , 2018, BMC Medicine.

[7]  A. Kesselheim,et al.  Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov , 2018, BMJ Open.

[8]  E. Cobo,et al.  Are CONSORT checklists submitted by authors adequately reflecting what information is actually reported in published papers? , 2018, Trials.

[9]  S. Lewis,et al.  Guidelines for the Content of Statistical Analysis Plans in Clinical Trials , 2017, JAMA.

[10]  A. Marshall,et al.  A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines , 2017, BMC Medical Research Methodology.

[11]  Victoria Cornelius,et al.  Embracing model-based designs for dose-finding trials , 2017, British Journal of Cancer.

[12]  S. Heritier,et al.  The role of adaptive trial designs in drug development , 2017, Expert review of clinical pharmacology.

[13]  Gail Pearson,et al.  Efficient design of clinical trials and epidemiological research: is it possible? , 2017, Nature Reviews Cardiology.

[14]  F. Bretz,et al.  Estimands and Their Role in Clinical Trials , 2017 .

[15]  S. Ruberg,et al.  Estimands in clinical trials – broadening the perspective , 2017, Statistics in medicine.

[16]  Frank Bretz,et al.  Estimands: discussion points from the PSI estimands and sensitivity expert group , 2017, Pharmaceutical statistics.

[17]  R. Agha,et al.  Preferred reporting of case series in surgery; the PROCESS guidelines. , 2016, International journal of surgery.

[18]  P. Tugwell,et al.  CONSORT 2010 statement: extension to randomised pilot and feasibility trials , 2016, British Medical Journal.

[19]  David Moher,et al.  CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. , 2016, Journal of clinical epidemiology.

[20]  D. Berry,et al.  Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project , 2016, Trials.

[21]  Rong Tang,et al.  Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013 , 2016, Therapeutic innovation & regulatory science.

[22]  J. Ware,et al.  Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. , 2016, The Journal of investigative dermatology.

[23]  T. Vos,et al.  Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.

[24]  M. Dimairo.  The Utility of Adaptive Designs in Publicly Funded Confirmatory Trials , 2016 .

[25]  M. Dimairo,et al.  Adaptive designs undertaken in clinical research: a review of registered clinical trials , 2016, Trials.

[26]  E. Russek-Cohen,et al.  CBER’s Experience With Adaptive Design Clinical Trials , 2016, Therapeutic innovation & regulatory science.

[27]  Frank Bretz,et al.  Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls , 2015, Statistics in medicine.

[28]  S. Todd,et al.  Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials , 2015, Trials.

[29]  S. Todd,et al.  An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review , 2015, PloS one.

[30]  S. Todd,et al.  Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials , 2015, Trials.

[31]  D. Berry,et al.  Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study , 2015, Clinical research and regulatory affairs.

[32]  D. Altman,et al.  COS-STAR: a reporting guideline for studies developing core outcome sets (protocol) , 2015, Trials.

[33]  G. Guyatt,et al.  CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement , 2015, BMJ : British Medical Journal.

[34]  K. Lee,et al.  Korean translation of the CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2014, Epidemiology and health.

[35]  M. Posch,et al.  Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency , 2014, Trials.

[36]  U. Lorch,et al.  Three steps to writing adaptive study protocols in the early phase clinical development of new medicines , 2014, BMC Medical Research Methodology.

[37]  J. Oud,et al.  Developments in statistical evaluation of clinical trials , 2014 .

[38]  B. Feldman,et al.  Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. , 2014, Journal of clinical epidemiology.

[39]  Yuanxin Rong.  Regulations on Adaptive Design Clinical Trials , 2014 .

[40]  J. Wathen,et al.  Adaptive Design: Results of 2012 Survey on Perception and Use , 2014, Therapeutic innovation & regulatory science.

[41]  Shein-Chung Chow,et al.  Adaptive clinical trial design. , 2014, Annual review of medicine.

[42]  Eberechukwu Onukwugha,et al.  Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer , 2014, BMC Medical Research Methodology.

[43]  Vladimir Dragalin,et al.  Adaptive Clinical Trials: Overview of Phase III Designs and Challenges , 2014, Therapeutic innovation & regulatory science.

[44]  T. Jaki.  Designing Multi-arm Multi-stage Clinical Studies , 2014 .

[45]  David Moher,et al.  The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development , 2013, Journal of Medical Case Reports.

[46]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[47]  Thomas Jaki,et al.  Uptake of novel statistical methods for early-phase clinical studies in the UK public sector , 2013, Clinical trials.

[48]  B. Levin,et al.  Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop , 2012, Clinical trials.

[49]  Paul Hines,et al.  Operational Challenges and Solutions with Implementation of an Adaptive Seamless Phase 2/3 Study , 2012, Journal of diabetes science and technology.

[50]  C. Coffey,et al.  Adaptive trial designs: a review of barriers and opportunities , 2012, Trials.

[51]  Shein-Chung Chow,et al.  Benefits, challenges and obstacles of adaptive clinical trial designs , 2011, Orphanet journal of rare diseases.

[52]  R. Porcher,et al.  Adaptive methods: when and how should they be used in clinical trials? , 2011, Therapie.

[53]  Robert O'Neill,et al.  Adaptive design clinical trials and trial logistics models in CNS drug development , 2011, European Neuropsychopharmacology.

[54]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[55]  Christy Chuang-Stein,et al.  FDA Draft Guidance on Adaptive Design Clinical Trials: Pfizer's Perspective , 2010, Journal of biopharmaceutical statistics.

[56]  D. DeMets,et al.  Review of Draft FDA Adaptive Design Guidance , 2010, Journal of biopharmaceutical statistics.

[57]  Judith Quinlan,et al.  Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development , 2010, Clinical trials.

[58]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.

[59]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials , 2010, Obstetrics and gynecology.

[60]  D. Moher,et al.  Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.

[61]  Michael J. Rosenberg.  The agile approach to adaptive research , 2010 .

[62]  H. Hemilä.  Citation bias in the CONSORT comments on blinding , 2010 .

[63]  Draft Guidance.  Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .

[64]  Donald A. Berry,et al.  Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .

[65]  Frank Bretz,et al.  Adaptive designs for confirmatory clinical trials , 2009, Statistics in medicine.

[66]  B. Muthén,et al.  Adaptive designs for randomized trials in public health. , 2009, Annual review of public health.

[67]  Shein-Chung Chow,et al.  Adaptive design methods in clinical trials – a review , 2008, Orphanet journal of rare diseases.

[68]  D. Moher,et al.  CONSORT for reporting randomised trials in journal and conference abstracts , 2008, The Lancet.

[69]  D. Moher,et al.  CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration , 2008, PLoS medicine.

[70]  C. Coffey,et al.  Adaptive Clinical Trials , 2008, Drugs in R&D.

[71]  Vladimir Dragalin,et al.  Adaptive Designs: Terminology and Classification , 2006 .

[72]  Michael Krams,et al.  Implementing Adaptive Designs: Logistical and Operational Considerations , 2006 .

[73]  R T O'Neill.  FDA's critical path initiative: a perspective on contributions of biostatistics. , 2006, Biometrical journal. Biometrische Zeitschrift.

[74]  A. Koch.  Confirmatory Clinical Trials with an Adaptive Design , 2006, Biometrical journal. Biometrische Zeitschrift.

[75]  A. Gould.  How Practical are Adaptive Designs Likely to be for Confirmatory Trials? , 2006, Biometrical journal. Biometrische Zeitschrift.

[76]  P Bauer,et al.  Application of Adaptive Designs – a Review , 2006, Biometrical journal. Biometrische Zeitschrift.

[77]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[78]  Paul Gallo,et al.  Operational challenges in adaptive design implementation , 2006, Pharmaceutical statistics.

[79]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[80]  O. Keene,et al.  Adaptive designs for pivotal trials: discussion points from the PSI Adaptive Design Expert Group , 2006, Pharmaceutical statistics.

[81]  W. Brannath,et al.  The advantages and disadvantages of adaptive designs for clinical trials. , 2004, Drug discovery today.

[82]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[83]  B. Efron.  Bootstrap Methods: Another Look at the Jackknife , 1979 .

[84]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.